Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

September 30, 2012

The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

Rearrangements of the kinase (ALK) gene are found in about 5% of all lung cancers. In previous uncontrolled studies, crizotinib has been shown to induce significant clinical responses in patients with advanced ALK-positive lung cancer.

"This study is the first head-to-head comparison of crizotinib with standard chemotherapy in this patient group," said lead study author Dr Alice Shaw from Massachusetts General Hospital Cancer Center in Boston, USA. "In ALK-positive patients who have been previously treated with first-line, platinum-based chemotherapy, crizotinib is superior to standard single-agent chemotherapy in terms of response, progression-free survival and quality of life. These results establish crizotinib as the standard of care for patients with advanced, previously treated, ALK-positive lung cancer."

The current global randomized study compared the efficacy and safety of crizotinib with standard chemotherapy with or , in 347 patients with ALK-positive lung cancer who had already been treated with chemotherapy.

The study showed that crizotinib prolonged progression-free survival to a median of 7.7 months compared to 3.0 months among those patients who received the chemotherapy (HR 0.49; 95% CI 0.37-0.64 ; P<0.0001). The overall response rate was also significantly higher in those treated with crizotinib (65% vs 20%; P<0.0001).

So far, the analysis of the overall survival rate with the two drugs is still immature, Dr Shaw said. That is, not enough events have occurred to draw meaningful conclusions.

"It is important to note that there was significant crossover in this study," Dr Shaw said. "Patients who were randomized to receive chemotherapy and had were allowed to crossover to receive crizotinib. Hence, the majority of patients on the chemotherapy arm actually did receive crizotinib. This makes determination of overall survival benefit very challenging."

In this study, certain side-effects were more frequent with crizotinib compared with single-agent chemotherapy. "However, despite this, patients still reported improved quality of life on crizotinib compared with chemotherapy," Dr Shaw said.

Commenting on the data, Dr Enriqueta Felip, Head of the Lung Cancer Unit in Oncology Department at Vall d'Hebron University Hospital in Barcelona, Spain and chair of the ESMO 2012 Metastatic NSCLC track (not involved in the study) said: "The results of this study are of great clinical relevance. Crizotinib, an oral drug, is more effective than standard in previously treated lung cancer patients with a specific molecular alteration, ALK. This is the first randomized study in a group of lung cancer patients selected precisely because they have ALK-positive tumors. After the worldwide implementation of targeted therapy in lung cancer patients defined by another molecular alteration —EGFR mutation, this is the second group of lung cancer patients to clearly benefit from a therapy directly targeting a molecular alteration. The results of this study represent a significant step towards individualized therapy in patients."

Explore further: Crizotinib reduces tumor size in patients with ALK positive lung cancer

Related Stories

Crizotinib reduces tumor size in patients with ALK positive lung cancer

September 6, 2012
Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard ...

First and only therapeutic drug for ALK-positive lung cancer approved

August 31, 2011
In a major triumph for personalized medicine, the FDA approved the drug crizotinib for use with the lung cancer type known as ALK-positive.

Study examines drug resistance in ALK positive lung cancer

January 19, 2012
Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell ...

Benefit of targeted lung cancer therapy confirmed

June 3, 2011
A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest ...

ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium

July 5, 2011
ALK rearrangement has been found in 9.6% of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1%, reflecting how many patients might benefit from targeted therapies such ...

Recommended for you

Cancer vaccines need to target T cells that can persist in the long fight against cancer

September 25, 2017
Cancer vaccines may need to better target T cells that can hold up to the long fight against cancer, scientists report.

MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer

September 25, 2017
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing ...

Lung cancer treatment could be having negative health effect on hearts

September 25, 2017
Radiotherapy treatment for lung cancer could have a negative effect on the health of your heart new research has found.

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.